STAT3 and hepatocellular carcinoma: A study report involving DCA and Newcastle disease virus combination treatment against hepatocellular carcinoma indicates that the PDK inhibitor DCA significantly reduced lactate release, STAT3 activation, IDO1 upregulation, and MDSC infiltration in Newcastle disease virus-treated hepatocellular carcinoma.